Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chuan Gu

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
The Lancet. Respiratory Medicine|March 29, 2021
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label studyYuankai Shi, Xingsheng Hu, Shucai Zhang, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Cell Research|August 2, 2014
The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodesHong-Mei Wang, Yun-Fei Xu, Shang-Lei Ning, et al.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue|March 28, 2019
[A twenty-year review of clinical liver transplantation]Zhongyang Shen, Chuan Gu, Hong Zheng, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
The Lancet. Respiratory Medicine|March 29, 2021
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label studyYuankai Shi, Xingsheng Hu, Shucai Zhang, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Cell Research|August 2, 2014
The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodesHong-Mei Wang, Yun-Fei Xu, Shang-Lei Ning, et al.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue|March 28, 2019
[A twenty-year review of clinical liver transplantation]Zhongyang Shen, Chuan Gu, Hong Zheng, et al.
Pageof 6